The Motley Fool·2025-12-24 20:35Core Viewpoint - Dynavax Technologies is set to be acquired by Sanofi for $15.50 per share, valuing the company at approximately $2.2 billion, representing a 39% premium over its previous closing stock price [3]. Group 1: Acquisition Details - Sanofi will initiate a tender offer to purchase Dynavax's stock at $15.50 per share in cash [3]. - The acquisition deal is expected to close in the first quarter of 2026 [3]. Group 2: Market Reaction - Following the announcement, Dynavax's stock price surged by over 38%, reaching $15.38 [1][4]. - The market capitalization of Dynavax is currently around $1.3 billion [4]. Group 3: Product Synergies - The merger will combine Dynavax's adult hepatitis B vaccine and shingles vaccine candidate with Sanofi's extensive global scale and commercial distribution network [6]. - Dynavax's adult hepatitis B vaccine offers a two-dose regimen that provides protection more quickly than traditional three-dose vaccines [7]. - The shingles vaccine candidate from Dynavax is in early clinical development, targeting protection against a viral disease that can cause severe pain [8].